hyun_seoul said:Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.
All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.
Worth separating that from compounded supply, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.
pete_manc_UK said:The dose-response is real but shallow at the top.
Bookmarking. The distinction being drawn above is the one nobody else makes. Printing the relevant bit and taking it with me.
hyun_seoul said:Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.
I read this differently from hyun_seoul, on substance rather than tone. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsThe figures, for anyone assembling their own picture. Two things anyone can check: a state licence number for a 503A, and an FDA outsourcing-facility registration for a 503B. Both are publicly searchable, and a pharmacy unwilling to give you either has answered the question.